Showing 5411-5420 of 5771 results for "".
- Compact Imaging Collaborates with Novartis to Accelerate Development of Home Monitor for AMD and DRhttps://modernod.com/news/compact-imaging-collaborates-with-novartis-to-accelerate-development-of-home-monitor-for-amd-and-dr/2479735/Compact Imaging (CI), a developer of miniaturized optical coherence tomography (OCT) devices, announced the signing of a collaboration agreement with Novartis Pharma under which Novartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in adva
- International Innovators in Medical and Surgical Eye Health to Convene in Chicago to Advance Patient Carehttps://modernod.com/news/international-innovators-in-medical-and-surgical-eye-health-to-convene-in-chicago-to-advance-patient-care/2479737/Thousands of eye physicians and surgeons this week will convene in Chicago to attend AAO 2018, the American Academy of Ophthalmology’s 122nd annual meeting. This gathering is an opportunity to hear global leaders in medical and surgical eye care discuss issues affecting patients’ lives, from the
- Ellex Launches Eye Prime Ultrasound Solutionhttps://modernod.com/news/ellex-launches-eye-prime-new-ultrasound-solution/2479738/Ellex Medical Lasers Limited announced the preview of Eye Prime, a next generation ultrasound platform, at the 2018 annual meeting of the AAO. The system’s imaging capability makes it a important diagnostic tool in ophthalmology, and when paired with Ellex’s proprietary Reflex Techology, offers a
- EyeMD EMR Healthcare Systems to Debut its EyeMD Electronic Medical Records 2.0 Releasehttps://modernod.com/news/eyemd-to-debut-its-eyemd-electronic-medical-records-2-0-release/2479739/EyeMD EMR Healthcare Systems, a provider of electronic medical records software designed specifically for ophthalmologists, announced the debut of EyeMD EMR 2.0 at the 2018 American Academy of Ophthalmology’s Annual Meeting in Chicago. “EyeMD EMR 2.0 is the result of years of research and
- Reay H. Brown, MD, Joins Sight Sciences as Chief Medical Officerhttps://modernod.com/news/reay-h-brown-md-joins-sight-sciences-as-chief-medical-officer/2479741/Sight Sciences announced that Reay H. Brown, MD, has joined the company as Chief Medical Officer (CMO). Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma. He was the original inventor of trabecular microbypass stenting, which has served as t
- Optovue Highlights World’s First OCTA Metrics and Corneal Measurement Method at AAO 2018https://modernod.com/news/optovue-highlights-worlds-first-octa-metrics-and-corneal-measurement-method-at-aao-2018/2479742/Optovue will showcase AngioAnalytics, the world’s first OCTA blood vessel measurement technology to help physicians manage diseases that cause progressive blindness, and 3D PAR, its three-dimensional projection artifact removal software at the American Academy of Ophthalmology Annual Meeting (AAO
- Santen Launches Verkazia for Children and Adolescents with Severe Allergic Eye Conditionhttps://modernod.com/news/santen-launches-verkazia-for-children-and-adolescents-with-severe-allergic-eye-condition/2479744/Santen UK announced the launch of Verkazia eye drops emulsion containing 0.1% (1mg/ml) ciclosporin for the treatment of the rare disease severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. Verkazia, which has been granted orphan drug status, provides a much-n
- Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy Studyhttps://modernod.com/news/eylea-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial/2479745/Regeneron Pharmaceuticals announced that the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its 1-year (52-week) primary endpoint and key secondary endpoints. On the primary end
- Foundation Fighting Blindness Launches Retinal Degeneration Fundhttps://modernod.com/news/foundation-fighting-blindness-launches-retinal-degeneration-fund/2479747/The Foundation Fighting Blindness announced the creation of the first Retinal Degeneration Fund (RD Fund), a wholly owned, 501(c)(3) not-for-profit subsidiary focused on making venture philanthropy investments to furt
- Eyevance Pharmaceuticals Acquires Exclusive Rights to Commercialize Flarex in the United Stateshttps://modernod.com/news/eyevance-pharmaceuticals-acquires-exclusive-rights-to-commercialize-flarex-in-the-united-states/2479751/Eyevance Pharmaceuticals announced the acquisition of Flarex (fluorometholone acetate ophthalmic suspension) 0.1% from Novartis AG. Flarex, approved in the United States, is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea,